ITGB2 and Sepsis: In conclusion, we report that a ligand-specific anti-Mac-1 therapy is superior to unspecific, conventional blocking strategies —in particular in conditions that are driven by inflammation and impaired host defense simultaneously, such as polymicrobial sepsis.